欢迎来到天天文库
浏览记录
ID:33913834
大小:1.67 MB
页数:38页
时间:2019-03-01
《参芪糖肾安冲剂治疗dn相关证候及相关指标临床疗效观察》由会员上传分享,免费在线阅读,更多相关内容在学术论文-天天文库。
1、中文摘要导师张振忠教授依据中医药理论,结合多年临床经验积累,采用益气养阴、健脾补肾、活血化瘀的治疗原则,精心配伍组方而研制成参芪糖肾安冲剂,经过临床反复实践证明确有一定疗效。目的:扩大临床试验,进一步客观的评价该药改善早期气阴两虚,脾肾虚弱,瘀浊阻滞DN患者的中医临床症状,降低空腹血糖、尿蛋白的确切疗效。进一步对该药的安全性、稳定性作出评价。方法:对于符合诊断标准、纳入标准和排出标准筛选的合格受试对象62例按照就诊顺序随机分为治疗组(32例)和对照组(30例)。治疗组给予参芪糖肾安冲剂,口服,一次89,一日3次。对照药给予厄贝沙坦,口服,150mg,每日1次。3周为一疗程,
2、治疗2个疗程。观察两组患者治疗治疗前、2周、4周、6N主要临床症状及治疗前、治疗3周、6周FBG、餐后2hBG、Hbhlc、u-Alb、24hUP、血脂、肾功,分别比较两组治疗前后上述指标的变化情况,并对参芪糖肾安冲剂治疗DN安全性进行检测。结果:两组在治疗早期气阴两虚,脾肾虚弱,瘀浊阻滞DN患者,尿微量白蛋白疗效比较:治疗组84.37%、对照组90%,无明显差异性(P>0.05);中医证候综合疗效比较:治疗组87.5%,对照组40%;差异性显著(PO.
3、05);但两组在改善中医临床症状、调节血糖及糖化血红蛋白等方面比较有明显差异性(P4、ndreIated—bymptomsABSTRACTShenqiTangshenAnGranulewascreatedbyProfessorZhangZhenzhongonthetheoryofTCM,theprincipleofstrengtheningqiandnourishingyin,strengtheningspleenandkidney,activatingbloodandremovingstasis,combiningwithhisyearsofaccumulatedclinicalexperience,whichshowscertaineffectsincl5、inicaltreatmentaftermanytimesofpractice.Objective:Toevaluatethetreatingeffect,securityandstabilityofthisgranulebyadministratingitonabiggerexpansionofclinicalDNpatientswithqiandyindeficiency,weaknessofKidneyandspleenandbloodstasis.TOcheckthemedicine’Seffectsonreducingbloodglucosebeforedieta6、ndthecontentofurineprotein.Methods:The62cases,whomeetthediagnosticcriteria,standardedsubjectsqualifiedfortreatment,wererandomlydividedintotreatmentgroup(32cases)andcontrolgroup(30cases).TreatmentgroupweregivenShenqiTangshenanGranule,orally,89ev150mgonce,perday,3erytime,3timesperday.Irbesar7、tanweregiven,orally,weeksasacourseoftreatment,withtwocourses.Themainclinicalsymptoms,FBG,postprandial2hBG,HbAlc,u-Alb,24hUP,bloodlipids,renalfunctionwereobservedbeforetreatment,2weeks,4weeks,and6weeksinthetwogroups.AndShenqiTangshenAnGranule’Ssafetywascheckeda
4、ndreIated—bymptomsABSTRACTShenqiTangshenAnGranulewascreatedbyProfessorZhangZhenzhongonthetheoryofTCM,theprincipleofstrengtheningqiandnourishingyin,strengtheningspleenandkidney,activatingbloodandremovingstasis,combiningwithhisyearsofaccumulatedclinicalexperience,whichshowscertaineffectsincl
5、inicaltreatmentaftermanytimesofpractice.Objective:Toevaluatethetreatingeffect,securityandstabilityofthisgranulebyadministratingitonabiggerexpansionofclinicalDNpatientswithqiandyindeficiency,weaknessofKidneyandspleenandbloodstasis.TOcheckthemedicine’Seffectsonreducingbloodglucosebeforedieta
6、ndthecontentofurineprotein.Methods:The62cases,whomeetthediagnosticcriteria,standardedsubjectsqualifiedfortreatment,wererandomlydividedintotreatmentgroup(32cases)andcontrolgroup(30cases).TreatmentgroupweregivenShenqiTangshenanGranule,orally,89ev150mgonce,perday,3erytime,3timesperday.Irbesar
7、tanweregiven,orally,weeksasacourseoftreatment,withtwocourses.Themainclinicalsymptoms,FBG,postprandial2hBG,HbAlc,u-Alb,24hUP,bloodlipids,renalfunctionwereobservedbeforetreatment,2weeks,4weeks,and6weeksinthetwogroups.AndShenqiTangshenAnGranule’Ssafetywascheckeda
此文档下载收益归作者所有